Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ACRS
SELLAclaris Therapeutics, Inc. · Healthcare · United States · $730M · Avg Vol: $10M/d
COMPANY DESCRIPTION
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel small molecule therapies for immuno-inflammatory diseases. The company leverages its proprietary KINect™ platform to identify and advance drug candidates that selectively modulate specific immune pathways, with a current focus on dermatology and rheumatology. Aclaris aims to address significant unmet medical needs with potential first-in-class or best-in-class treatments.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 29.8M | 31.2M | 18.7M | 7.8M | -35.9% | 8.4M | 5.7M | 5.4M | -17.3% |
| EPS | — | -0.64 | -1.27 | -1.71 | -0.53 | — | -0.55 | -0.66 | -0.83 | — |
| Shares | — | 139.7M | 70.9M | 107.9M | 120.5M | -13.7% | 139.7M | — | — | — |
| Debt | 0.7M | 0.7M | 0.4M | — | — | -21.6% | 2.0M | — | — | — |
| Equity | — | 197.6M | 157.2M | 155.6M | 103.1M | -19.5% | — | — | — | — |
| Op CF | — | -67.6M | -78.3M | -20.1M | -47.1M | — | -52.2M | — | — | — |
| Inv CF | — | 12.6M | 46.2M | -69.8M | 48.4M | — | — | — | — | — |
| Fin CF | — | 72.9M | 26.7M | 74.5M | -5.9M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ACRS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ACRS | Aclaris Therapeutics, Inc.(you) | $730M | 20 | SELL |
| AURA | Aura Biosciences, Inc. | $729M | 23 | SELL |
| DRUG.CN | Bright Minds Biosciences Inc. | $727M | 24 | SELL |
| BBOT | BridgeBio Oncology Therapeutics, Inc. | $707M | 17 | STRONG SELL |
| SLDB | Solid Biosciences Inc. | $771M | 24 | SELL |
| DSGN | Design Therapeutics, Inc. | $736M | 25 | SELL |
| KURA | Kura Oncology, Inc. | $922M | 20 | STRONG SELL |
| ANL | Adlai Nortye Ltd. | $805M | 24 | SELL |
| PHAT | Phathom Pharmaceuticals, Inc. | $912M | 19 | STRONG SELL |
| ACHV | Achieve Life Sciences, Inc. | $626M | 17 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.7%